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A 51-year-old female was diagnosed preoperatively to have a pheochromocytoma producing ACTH. This
diagnosis was based upon her paroxysmal hypertension, hyperpigmentation, and hypokalemia. Elevated
levels of serum and urine corticosteroids, plasma ACTH, urinary VMA, and catecholamines fell after a right
adrenal pheochromocytoma was removed. Subsequently this tumor was found to have a high content of
ACTH. Review of the literature indicates a mortality rate of 57% for this syndrome. Proper preoperative
recognition and management can result in total cure.
The syndrome of ectopic production of ACTH, in which a corticotrophin-like
substance is produced by non-pituitary neoplasms may occur with various types of
tumors [1,2]. Most cases fall into one offour general categories: (1) oat cell bronchial
carcinoma, (2) endocrine tumors of foregut-derived tissue, (3) ovarian tumors, and
(4) pheochromocytoma and related tumors [3]. In the present report we describe a
patient with an ACTH-producing pheochromocytoma and review the literature on
chromaffin tumors associated with hypercortisolism.
CASE REPORT
A 51-year-old white female was admitted to the Yale-New Haven Hospital with
hypertension, hyperpigmentation, weight loss, and emotional lability. She was well
until five months prior to admission, when she sought medical attention because of
anxiety. Her blood pressure at that time was 130/80 mm Hg. Serum thyroxine was
normal. In the ensuing three months, she developed what she described as a
"cortisone face," having remembered her appearance after receiving cortisone for a
nine-month period 22 years prior to admission as experimental therapy for Rh
incompatibility. She also noted a change in body habitus with central redistribution
of body fat, although she was not obese, and had lost ten pounds of weight. She
developed ankle edema, easy bruising, poor healing of wounds, increased facial and
body hair, facial acne, proximal muscle weakness, generalized increased skin
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All rights of reproduction in any form reserved.pigmentation despite minimal sun exposure, marked emotional lability, fine, thin
skin, and the cessation ofpreviously regular menses. She also complained of repeated
episodes of tremulousness, profuse sweating, and headaches. Five weeks prior to
admission, she began to take a thiazide diuretic with KCI supplement as therapy for
hypertension. These medications were discontinued one week prior to admission and
at the time of hospitalization the only medication was ferrous sulfate. She had
smoked one pack of cigarettes a day for 35 years. There was no family history of
endocrine disease; several members of the family had prominent eyes but were
euthyroid.
On physical examination, the patient appeared anxious and had "moon facies."
The blood pressure was 170/110 mm Hg in both arms supine and sitting, respiratory
rate 17, the pulse 120 and regular, and the temperature was 98°F. The skin was thin
and smooth with diffusely increased pigmentation, numerous ecchymoses and
petechiae. She also had fine facial hair. There were no hyperpigmented scars or
purple striae. She had bilaterally prominent eyes without proptosis or lid lag.
Funduscopic examination was normal as were fields of vision by confrontation. The
thyroid gland was normal. There was no prominence of the supraclavicular or
dorsocervical fat pads nor any lymphadenopathy. The heart and lungs were normal.
The vertical span of the liver was 13 cm in the right midclavicular line and there were
no abdominal masses. Rectal, pelvic, and neurological examinations were normal.
She had 1+ pretibial edema.
The hematocrit was 47% and the white cell count 19,000 with 91% neutrophils, 2%
band forms, 2% lymphocytes, and 5% monocytes. Platelet count was 420,000. Serum
sodium was 147 mEq/L, potassium 2.2 MEq/L, bicarbonate 39 mEq/L, and chloride
91 mEq/ L. The BUN was 23 mg/dl and the creatinine was 1.1 mg/dl. Random serum
glucoses varied between 105 and 170 mg/dl. Total serum calcium was11.3 mg/dl and
phosphate 2.8 mg/ dl. Two days later, after the discontinuation of all medication,
repeat values were 10.4 mg/dl and 3.3 mg/dl, respectively. The serum albumin was
3 g/dl, a 24 hour urine sample contained 1.3 g of protein. Serum calcitonin [4],
prolactin [5], and parathyroid hormone [6] were normal. Routine chest x-ray, full
lung tomograms, sella turcica films, and formal fields of vision by Goldmann
perimetry were normal. Electrocardiogram was normal; there were no premature
beats. The serum thyroxine was 3.2 micrograms/ dl (normal range 4.6-9.2), and the
estimated free thyroxine 0.5 mcg/dl (normal range 1.0-2.1). Serum TSH was
undetectable. 1-131 uptake was 7% and diffusely decreased. Total blood volume was
normal [7]. Pertinent hormone studies are shown in Table 1.
An abdominal ultrasound examination (Fig. 1) identified a right cystic adrenal
mass and subsequent abdominal "CAT" scan (Fig. 2) confirmed the right adrenal
mass and demonstrated left adrenal enlargement. Abdominal aortic angiography
characterized the right adrenal mass as cystic (Fig. 3). Blood pressure rose briefly to
260/140 mm Hg during this study. Other endocrine neoplasia were not present based
on the normal sella films, calcitonin, parathyroid hormone, serum glucose levels, and
thyroid scan. Serum calcium became normal after thiazide diuretic therapy was
discontinued.
The data presented in Table 1 indicated hyperfunctioning of both the adrenal
cortex and medulla. The clinical diagnosis was consequently ectopic ACTH syn-
drome due to a pheochromocytoma. Therefore, preoperative management consisted
of spironolactone administration to correct the hypokalemia and lower the pressure
along with phenoxybenzamine as specific antihypertensive therapy for the presumed
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TABLE I
Day 3 Low Day 2 High
Baseline Dose Dex Dose Dex Post-Op Normal Values
Cortisol
8 AM 135 125 164 12-25 mcg/dl
8 PM 75 less than 12 mcg/dl
Urine 17 OH 88.4 80.3 16 3-10 mg/24 hr
Urine 17 KS 53.3 48.2 47.9 5-15 mg/24 hr
ACTH [8]
8 AM 180 <10 10-80 pg/ml
8 PM 226
V.M.A. [9] 33 <5 mg/24 hr
Norepinephrine 215 11.2 0-100 mcg/24 hr
(total) calculated as nor-
Epinephrine [10] 112 epinephrine.
Renin [I 1] 2.5 0.6-4.6 ng/ml/hr
pheochromocytoma. Oral liothyronine therapy was begun to ensure euthyroid status.
Sympathetic blocking drugs as well as pressor agents were "on standby" during
surgery and an arterial line and Swan-Ganz catheter were placed preoperatively.
On the ninth hospital day the right adrenal tumor was removed. Blood pressure fell
to normal as soon as the right adrenal vein was ligated. Palpation of the left adrenal
gland revealed a small firm mass, and therefore the left adrenal gland was also
removed.
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FIG. 1. Abdominal ultrasound showing a 3 to 4 cm cystic mass (arrow) in the region of the right adrenal gland.184 FORMAN ET AL.
FIG. 2. Computerized Axial Tomogram, transaxial view, showing a large right adrenal mass (double arrows) and a
slightly enlarged left adrenal gland (single arrow).
FIG. 3. Arteriogram-delayed film after selective right middle adrenal artery injection. Thecystic nature ofthe tumor
is apparent.ECTOPIC ACTH DUE TO PHEOCHROMOCYTOMA
PATHOLOGY
The right adrenal (Fig. 4, top) weighed 100 grams and included a partly cystic gray-
brown mass, 8 x 5 cm in cross section containing approximately 40 cc ofhemorrhagic
fluid within the cystic space. This mass was an encapsulated medullary tumor
showing the typical light microscopic features ofa pheochromocytoma (Fig. 5). Thin
section electron microscopy showed membrane-bound osmiophilic granules of two
types: some were filled with electron-dense material and others showed a clear halo,
corresponding to epinephrine- and norepinephrine-containing granules, respectively
[12] (see Fig. 6).
The contralateral adrenal (Fig. 4, bottom) weighed 22 grams and was generally
thickened, with a grossly evident 1 cm zone of poorly demarcated hyperplasia. This
lesion, which consisted mostly of clear cells but also some compact cells and necrotic
foci, merged at its periphery with diffusely hyperplastic adrenal cortex. The residual
medullary tissue was normal in appearance.
Cystic fluid was assayed for ACTH by BioScience Laboratories [8] and was
reported to contain over 10 ng/ml. This fluid was also assayed for ACTH activity by
Dr. David Orth at Vanderbilt University School of Medicine, and was found to
contain over 17.5 ng/ml [13]. Tissue assay for ACTH was also kindly performed by
Dr. Orth and was 180 ng/g wet tissue [14]. Plasma ACTH levels 2 days postopera-
tively were less than 10 pg/ml.
FIG. 4. The right adrenal gland (top) with the cystic pheochromocytoma. Note the thickened adrenal cortex. The left
adrenal (bottom) was enlarged with nodular hyperplasia of the cortex.
185FORMAN ET AL.
FIG. 5. Photomicrograph illustrating the pheochromocytoma. Nests of ovoid and spindle cells are separated by
vascular channels. Note laking of blood (right). (x 125)
LITERATURE REVIEW
In 1964 Bourgoignie et al. [15] reported a case of pheochromocytoma associated
with Cushing's syndrome and hyperaldosteronism. Their review of previous case
reports revealed eleven cases of adrenocortical hyperplasia or adenomata in patients
with chromaffin tumors. Medullary pheochromocytomas were associated with
cortical hyperplasia in four cases [16-19] and with both hyperplasia and adenomata
in two cases [20,21]. Two patients had a chemodectoma, a medullary pheochromocy-
toma, and an adrenocortical adenoma [22,23]. The literature prior to 1964 also
FIG. 6. Electron micrograph of tumor cells demonstrating two types of neurosecretory granules resembling both
epinephrine and norepinephrine containing vesicles (see text). (x 28,000).
186ECTOPIC ACTH DUE TO PHEOCHROMOCYTOMA
includes two additional patients [24-26] and since Bourgoignie's review, there have
been sixteen case reports of chromaffin tumors associated with hypercortisolism or
hyperplasia of the adrenal cortex. Of these, four are too brief to permit adequate
assessment [27,28], and three other cases are probably not due to ACTH production
by the chromaffin tumors, despite the presence of hypercortisolism [29-31]. In
particular, Mathison and Waterhouse [29] reported a case of Cushing's syndrome
secondary to a mixed cortico-medullary tumor in which corticosteroid production by
the tumor appears a more likely etiology than ectopic ACTH production. Medullary
thyroid carcinoma coexisted with a pheochromocytoma and adrenocortical hyper-
plasia in the case of Mathys et al. [30], so that idiopathic Cushing's disease or
production of ACTH by either tumor are plausible etiologies for the patient's
hypercortisolism. A selective mineralocorticoid excess was observed by Wilson et al.
[31] but had there been ectopic ACTH production, elevated glucocorticoid levels
would also have been expected.
Three other cases are equivocal, although consistent with ectopic ACTH produc-
tion by a pheochromocytoma. However, Bucalossi et al. [32] report no ACTH levels
in theirunique case of a mediastinal pheochromocytoma associated with signs of
hypercortisolism. The cases of Rambert et al. [33] and Gerasimenko et al. [34] are
also consistent clinically with the ectopic ACTH syndrome, but these authors
reported normal plasma ACTH levels (on isolated random samples) and no ACTH
determinations were made on the tumor tissue.
By itself the presence of tissue ACTH is not sufficient to establish a diagnosis of
ectopic ACTH syndrome in view of Liddle's findings ofdemonstrable ACTH activity
in tumor tissue extracts in 8% of patients without the ectopic ACTH syndrome [25].
For conclusive proof, five criteria should be satisfied: (1) clinical and laboratory
evidence of hypercortisolism should be present; (2) ACTH activity should be present
in tumor extracts; (3) plasma ACTH should be clearly elevated; (4) elevated ACTH
levels should be evident in the venous effluent from the tumor site; (5) ACTH activity
should fall after removal of the tumor. The case of Schteingart et al. [35] fulfilled the
first four ofthese criteria. Bourgoignie [15] and Meloni et al. [36] established elevated
tumor, but not plasma, ACTH levels in their cases. Both tissue and plasma ACTH
activities were reported in the cases of O'Neal et al. [26], Burmeister and Simon [37],
Berenyi et al. [38] as well as in the present case.
Several generalizations can be made after examination of these seven cases with
well documented ectopic production of ACTH. All of the patients were women, with
ages ranging from 26 to 67 years (mean 46) at diagnosis; all had unilateral
nonmetastatic adrenal medullary tumors, two of which were classified as paragangli-
omas [35,36]. Two had a slow indolent course more typical of idiopathic Cushing's
syndrome [26,37], whereas the remaining five had a clinical presentation most
compatible with ectopic ACTH production (marked weakness and disorientation,
hyperpigmentation and weight loss, with a rapid course). Four of the five patients
with the histologic diagnosis of pheochromocytoma had exhibited paroxysmal
hypertension.
Despite the apparent curability of this syndrome, since all the reported tumors
were nonmetastatic, the survival rate was only 43 percent. Three patients died of
surgical complications and another of pneumonitis before surgery was attempted.
The three patients who survived surgery, including the present case, have apparently
been cured. Our patient is alive and well 21/2 years after surgery requiring only
cortisone acetate 371/2 mg per day.
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DISCUSSION
The present case raises many points ofclinical and theoretical interest. Unlike most
previously reported cases, the diagnosis ofectopic ACTH production by a pheochro-
mocytoma was made preoperatively. Therefore the serious consequences ofmisdiag-
nosis, improper preoperatrive management, and postoperative complications were
averted. Ectopic ACTH production was suspected by the triad of hypertension,
hyperpigmentation, and hypokalemia. A pheochromocytoma was suspected because
of paroxysmal hypertension and proven by the VMA and catecholamine studies.
Another possibility considered was a mixed cortico-medullary tumor similar to the
one reported by Mathison and Waterhouse [29]. However, the presence ofhyperpig-
mentation led us to favor the ectopic ACTH diagnosis.
The reduced thyroid function tests observed preoperatively in our case are
attributable to the known suppressive effects of elevated corticosteroids on thyroid
function [39]. Circulating thyroxine, TSH, and 1-131 uptake, which were low
preoperatively, normalized after surgery. Epinephrine production increases after
corticosteroid administration, presumably due to the induction by glucocorticoids of
phenylethanolamine-N-methyltransferase (PNMT), the enzyme which converts nor-
epinephrine to epinephrine [40]. In the present case, urinary excretion ofepinephrine
was elevated and epinephrine-containing secretory granules were seen on electron
microscopy (Fig. 6). However, direct tumor tissue assay for PNMT, kindly per-
formed by Dr. Linda Hegstrand, showed minimal activity [41,42]. The exact
explanation for these findings is unclear.
Despite the good prognosis in the majority ofuncomplicated pheochromocytomas,
our review of the literature indicates an inordinately high morbidity and mortality in
those that produce ACTH. Despite the rarity of this syndrome, all patients with
Cushing's syndrome should be screened for catecholamine excess. Preoperative
recognition ofthe presence ofa pheochromocytoma in a patient with clinical features
of Cushing's syndrome is essential for effective management and cure of this
syndrome.
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